Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effects of 'Next Generation Beneficial Microbes', Akkermansia Muciniphila (AMF-01), on Long-term Improvements in Insulin Resistance in Otherwise Healthy Hyperglycaemic Adults

NCT05114018 is registered in ClinicalTrials.gov with A-Mansia Biotech S.A. as lead sponsor.

NCT NCT05114018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05114018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effects of 'Next Generation Beneficial Microbes', Akkermansia Muciniphila (AMF-01), on Long-term Improvements in Insulin Resistance in Otherwise Healthy Hyperglycaemic Adults
Lead sponsor
A-Mansia Biotech S.A.
Phase
Not applicable
Overall status
Completed
Start date
June 24, 2020
Completion date
August 31, 2023
Enrollment
143 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome, overweight and obesity, pre-diabetes